All In Biotech

Drug Trial Radar · NCT06911333

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

A Phase I/IIa Trial of AD1208, a Cell Cycle Inhibitor/MASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Mar 11, 2025

Primary completion

Jun 30, 2029

Study completion Feb 20, 2030

Sponsor

Lead sponsor
Avelos Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are: * Which dosage of AD1208 is safe and tolerable for participants? * What medical problems do participants have when taking AD1208? Participants will: * Take drug AD1208 every day up to 1 cycle at the least. * Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards. * Keep a diary of any adverse events and administrated drug

Conditions

  • Solid Tumor, Adult
  • Tumor, Solid
  • Solid Tumor
  • Solid Tumor, Unspecified, Adult
  • Solid Tumor Cancer
  • Solid Tumors Refractory to Standard Therapy
  • Solid Tumor in Advanced Stage

Interventions

  • AD1208Drug

    Up to 6 of cohorts will be applied sequentially in phase Ia part.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: At the end of Cycle 1 (each cycle is 21 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.